Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antihypertensive combination therapy.

M R Weir1

  • 1Division of Nephrology and Clinical Research Unit, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).

Journal of human hypertension·2012
Same author

Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Can the early elimination of calcineurin inhibitors result in clinical benefits?

Transplantation proceedings·2010
Same author

How early should blood pressure control be achieved for optimal cardiovascular outcomes?

Journal of human hypertension·2010
Same author

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.

Journal of human hypertension·2010
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Combination antihypertensive therapy offers improved blood pressure control compared to single-drug approaches. Utilizing low-dose combinations may enhance efficacy and tolerability for better hypertension management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Growing evidence suggests a need for more aggressive control of systemic arterial pressure below traditional 140/90 mmHg.
  • Existing antihypertensive therapies show historically poor control rates, with only 40-50% achieving control after 6 months.
  • High discontinuation rates of antihypertensive drugs indicate issues with education, efficacy, or tolerability.

Purpose of the Study:

  • To reevaluate traditional antihypertensive care, moving beyond single-agent titration.
  • To explore the benefits of combination antihypertensive therapy for improved blood pressure management.
  • To investigate the potential of low-dose combination therapy as an initial treatment strategy.

Main Methods:

  • Review of evidence supporting aggressive blood pressure control.

Related Experiment Videos

  • Analysis of single-agent therapy outcomes and discontinuation rates.
  • Evaluation of combination therapy principles, including dose titration and drug interactions.

    • Main Results:

    • Single-agent therapy demonstrates limited efficacy and high discontinuation rates.
    • Low-dose combination therapy may offer satisfactory blood pressure reduction with fewer adverse events.
    • Potential for complementary, additive, or synergistic effects when combining agents with different mechanisms.

    Conclusions:

    • Combination antihypertensive therapy is a promising approach for achieving lower blood pressure targets.
    • Low-dose combination therapy may be optimal for patients unresponsive to monotherapy or as initial treatment.
    • Addressing education, efficacy, and tolerability is crucial for improving antihypertensive care outcomes.